Tollip Regulates Proinflammatory Responses to Interleukin-1 and Lipopolysaccharide
Author(s) -
Arnaud M. Didierlaurent,
Brian Brissoni,
Dominique Velin,
Natalia Aebi,
Aubry Tardivel,
Edgar Käslin,
JeanClaude Sirard,
Georgi S. Angelov,
Jürg Tschopp,
Kimberly Burns
Publication year - 2006
Publication title -
molecular and cellular biology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.14
H-Index - 327
eISSN - 1067-8824
pISSN - 0270-7306
DOI - 10.1128/mcb.26.3.735-742.2006
Subject(s) - proinflammatory cytokine , tlr4 , biology , lipopolysaccharide , tumor necrosis factor alpha , microbiology and biotechnology , cytokine , mapk/erk pathway , signal transduction , tlr2 , toll like receptor , immune system , receptor , immunology , inflammation , innate immune system , biochemistry
Activation of interleukin-1 (IL-1) receptor (IL-1R), Toll-like receptor 2 (TLR2), and TLR4 triggers NF-kappaB and mitogen-activated protein kinase (MAPK)-dependent signaling, thereby initiating immune responses. Tollip has been implicated as a negative regulator of NF-kappaB signaling triggered by these receptors in in vitro studies. Here, deficient mice were used to determine the physiological contribution of Tollip to immunity. NF-kappaB, as well as MAPK, signaling appeared normal in Tollip-deficient cells stimulated with IL-1beta or the TLR4 ligand lipopolysaccharide (LPS). Similarly, IL-1beta- and TLR-driven activation of dendritic cells and lymphocytes was indistinguishable from wild-type cells. In contrast, the production of the proinflammatory cytokines, IL-6 and tumor necrosis factor alpha was significantly reduced after IL-1beta and LPS treatment at low doses but not at lethal doses of LPS. Tollip therefore controls the magnitude of inflammatory cytokine production in response to IL-1beta and LPS.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom